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A Newly Designed Nitinol Stent: Early
Clinical Experience in the Treatment of
Iliac Artery Stenoses and Occlusions
Objective: To investigate the effectiveness of the newly designed Niti-S stent
in the management of iliac arterial stenoses and occlusions.
Materials and Methods: Stenoses (n=25) or occlusions (n=5) in the iliac arter-
ies of 25 patients (30 limbs) were treated. The site of the lesions was the common
(n=15) or external (n=11) iliac artery, or both (n=4). Eight limbs were treated for
diffuse disease, six for highly eccentric lesion, five for occlusive lesion, and 11 for
failed angioplasty.
Results: In all patients, technical success was achieved without major compli-
cations. One death, not procedure-related, occurred within 30 days. Ankle-
brachial indexes improved from 0.63 0.30 to 0.99 0.21, and ischemic symp-
toms showed improvement in 22 patients (88%). Fontaine classifications before
stenting, namely IIa(n=3), IIb(n=16), III(n=2), and IV(n=4) improved to I(n=17),
IIa(n=5), and IV(n=3). Follow-up over a 27 (mean, 19.8 8)-month period showed
that cumulative patency rates were 95.8% at 1 year and 86.2% at 2 and 3 years.
No significant decrease in the mean ankle-brachial index was observed.
Conclusion: The Niti-S stent appears to be a safe and effective device for the
treatment of iliac stenoses and occlusions. These preliminary results require con-
firmation with a larger series. 
etallic stent placement has been widely accepted as safe and effective for
the treatment of iliac arterial stenoses or occlusions (1 4). The superiori-
ty of such procedures compared with percutaneous transluminal angio-
plasty (PTA) for the treatment of iliac arterial occlusive disease has been described:
meta-analysis of the results of both techniques has shown that the former has a higher
technical success rate, together with less risk of long-term failure (5).
Nitinol is an alloy of nickel and titanium, and a good material for use in a self-ex-
panding stent. It is flexible and suitable for transluminal placement below its transit
temperature, and above this temperature resumes its original annealed shape. Since
the report published by Dotter et al. in 1983 (6), several other reports have described
clinical and experimental application of the nitinol stent (7, 8). The Strecker,
Memotherm and Cragg stents are examples of nitinol stents which have recently be-
come available (9 11). The advantages of such stents for intravascular applications
are easy delivery, a high expansion rate, low metal to tissue ratio, and the lack of se-
vere neointimal proliferation (12 14). 
We recently designed and developed a nitinol, mesh-type, vascular stent interlaced
with a nitinol monofilament. For the evaluation of in-vivo feasibility, an experiment
involving dogs was performed (15), and to investigate the stent’s clinical effectiveness,
a clinical trial involving the management of iliac arterial stenoses and occlusions was
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MATERIALS AND METHODS
Under a protocol approved by an institutional review
board, a Niti-S stent (Taewoong, Seoul, Korea) was placed
in the iliac arteries of the 25 patients (30 limbs) between
10 March, 1998 and 4 August, 1999. Informed consent
was obtained from the 24 men and one woman involved,
whose mean age was 66.8 (range, 54 83) years. Coinci-
dent disease that may have predisposed the patients to vas-
cular disease included cigarette smoking [n=21 (84%)], ar-
terial hypertension [n=14(56%)], elevated serum choles-
terol [n=11(44%)], and diabetes mellitus [n=8(32%)].
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Fig. 1. The Niti-S consists of a monofila-
ment nitinol wire wound on the mandrel
in such a way that a series of interlacing
wires creates a spiral mesh around its
circumference. The distance between
bends is approximately 2mm, and both
ends of the wire are connected at the
central portion of the stent (arrow). The
leading and trailing ends of the stent are
coated with platinum, which helps identi-
fy them and facilitates deployment
(curved arrows). 
Fig. 2. A. Pelvic angiogram obtained in a 68-year-old insulin dependent diabetic man with left-sided Fontaine stage-IIb claudication
shows segmental occlusion of about 8cm involving the left common iliac artery, with opacification of the external iliac artery and numer-
ous collateral channels. The translesional mean pressure gradient was 50 mmHg.
B. Angiogram obtained after primary stent placement shows good patency of a previously occluded segment, and there is no residual
pressure gradient across the lesion. During follow-up lasting 23 months, the patient was free of symptoms.
B AMore than one coincident disease was present in 16 pa-
tients (64%). On the basis of the Fontaine classification
(16 17), the clinical symptoms included three patients
(12%) with mild claudication (Fontaine stage IIa), 16
(64%) with severe claudication (IIb), two (8%) with rest
pain (III), and four (16%) with tissue loss or gangrene (IV).
At patient presentation, vascular disease involved the com-
mon iliac arteries in 15 limbs, the external iliac arteries in
11, and both arteries in four. Lesions took the form of
stenosis of over 75% (n=25) or complete occlusion (n=5),
and their length varied from 2.0 to 10.0 (mean, 4.1) cm.
Arterial runoff was as follows: the ipsilateral superficial
femoral arteries were occluded in eight limbs, there was
stenosis of over 75% in five, and the profunda femoris
artery was occluded in one. 
Ankle-brachial indexes (ABI) and intravascular pressures
were measured before and after the procedure. Primary
stent placement was performed in cases involving diffuse
long segmental stenoses (greater than 5 cm; eight limbs),
highly eccentric lesions (those at one side of a vessel wall;
six limbs), or chronic occlusion (five limbs). In the remain-
ing 11 limbs, secondary stent placement was performed af-
ter failed PTA. The indication for stent placement was de-
piction of a residual stenosis of at least 30% at anteropos-
terior and oblique angiography after PTA. Residual
stenoses were a result of dissection or elastic recoil in five
and six limbs, respectively. 
The Niti-S stent was used in all patients. Its endoprosthe-
sis consisted of an annealed 0.08-inch monofilament nitinol
wire wound on the mandrel, thus creating a spiral mesh
(Fig. 1). At room temperature, a nitinol stent softens and
can be folded to a diameter of 2.5 mm without destroying
its memory. At deployment, the stent self-expands to a
predetermined diameter of 5 10 mm, with a length of 3
10 cm. Its mechanical properties and biocompatibility have
been previously described in detail (15). 
The ipsilateral femoral artery was punctured and a 7-Fr
long sheath (Cook, Bloomington, Ind., U.S.A.) with dilator
was located under fluoroscopic guidance. A 0.038-inch, an-
gled-tip, hydrophilic guide wire (Terumo, Tokyo, Japan)
with or without a 6-Fr angiographic catheter (Cook) was
used in the initial attempt to across the lesion. If this failed,
another attempt (the antegrade approach) was made from
the contralateral common femoral artery, using the “modi-
fied wire-loop” technique (18). After crossing the lesion
with the guide wire, the long sheath with dilator was ad-
vanced. The deployment technique for the Niti-S is not
complicated. In order to load the stent into the long sheath,
the former was first loaded into a 7-Fr short sheath, the
distal end of which was inserted into the valve at the proxi-
mal end of the long sheath, which had already been placed
at the desired site. The stent was delivered to the end of
the long sheath using a pusher catheter, and once in its
proper position, withdrawal of the long sheath permitted
its deployment and expansion. To achieve full expansion,
PTA after deployment was necessary in all patients. To ex-
clude the possibility of iatrogenic distal embolization, post-
procedural angiography was performed. Prior to stent de-
ployment, a 3000-IU heparin bolus was administrated; for
procedures lasting over two hours, infusions were repeat-
ed. One 325-mg aspirin tablet was prescribed daily, begin-
ning the night before the procedure, and was continued for
three months. Thrombolysis or atherectomy was not per-
formed. 
The clinical symptoms before and after treatment were
determined on the basis of the Fontaine classification.
Technical success was defined as exact deployment of the
stent, less than 25% residual stenosis, and restoration of
rapid, antegrade blood flow through the stent. Clinical suc-
cess was defined as symptom improvement of at least one
Fontaine stage. 
Patients were followed up clinically at 1, 3, and 6 months
after the procedure, and every 6 months thereafter. At
these intervals, a history was taken, ABIs were measured,
and color and duplex Doppler analyses of the stent were
performed. Follow-up digital subtraction angiography was
undertaken when clinical symptoms indicated the need for
this, or if ABI had deteriorated during the follow-up peri-
od. Occlusion or stenosis of more than 50% was seen as
restenosis, and for statistical analysis of the patency rates,
Kaplan-Meier survival analysis was used.
RESULTS
Stents were successfully implanted in all 30 limbs, a sin-
gle Niti-S stent being placed in each limbs; with no addi-
tional stent required. In one patient with long segmental
stenosis, the anterolateral central portion of a 6-cm-long
stent was compressed due to strong arterial wall recoil.
Repeated balloon dilation led to successful expansion,
however. The mean pressure gradient across the lesion de-
creased significantly, from 50.2 31.1 to 3.8 1.3 mmHg.
Residual stenosis of less than 25% remained in five limbs
(16.6%), but the residual pressure was minimal [range, 0
5 (mean, 3) mmHg]. Mean ABI increased from 0.63 0.3
before the procedure to 0.99 0.21 after, a difference
which according to the paired t test was statistically signifi-
cant (p<0.01). The clinical symptoms improved by at least
one Fontaine stage in 22 patients (88%), none of whom
showed deterioration in their clinical stage. Three days af-
ter stenting, Fontaine stage I was observed in 17 patients,
IIa in five, and IV in three. The symptoms of three Fon-
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giographic follow-up indicated that the internal iliac artery
was covered by the stent in 13 limbs, though patency was
maintained in all limbs with the exception of one with sig-
nificant stenosis. During the follow-up period, however,
this patient showed no clinical symptoms or signs. 
During follow-up of up to 27 (mean, 19.8 8) months,
during which time two patients were lost, the clinical stage
and ABI were well maintained. After 6, 12, and 24
months, ABIs were 0.99 0.09, 0.91 0.15, and 0.92
0.1, respectively. No patient showed a deterioration in
clinical stage or an ABI decline of greater than 0.15. In two
patients, restenosis was detected by follow-up Doppler
sonography at 3 and 21 months, respectively. In one of
these, intra-stent stenosis (75% of nominal diameter) was
confirmed by angiography and successfully treated with
PTA. The other patient declined further treatment. In addi-
tion to five limbs in which residual stenoses remained after
stent placement, a newly developed stenosis (less than
25%) in the distal portion of the stent was revealed by fol-
low-up sonography in two patients (two limbs). The
modality showed that the condition of both subsequently
remained stable, and further treatment was not attempted.
Between two and 18 (mean, four) months later, despite a
normally patent stent, bypass surgery was performed in
four patients (five limbs) because other foci of atheroscle-
rosis were seen distally or contralaterally. The cumulative
patency rates were 95.8% at 1 year and 86.2% at 2 and 3
years (standard error, 10%). 
No major procedure-related complications occurred. A
puncture site pseudoaneurysm was observed in one pa-
tient, though this was successfully obliterated by sono-
guided compression. One patient died of acute myocardial
infarction within one month of the procedure, and during
the follow-up period a further three died of diabetic ne-
phropathy (n=2) or rupture of an abdominal aortic aneur-
ysm (n=1).
DISCUSSION
Thirty complex lesions of the iliac artery were treated
with this newly designed nitinol monofilament stent (Niti-
S). Exact stent placement was possible in all patients and
the initial technical success rate was 100%. In our study,
the Niti-S stent showed several desirable features that
made it well-suited for the treatment of iliac stenoses and
occlusions. The 10-mm-diameter stent could be loaded into
a 7-Fr sheath, and is thus quite compressible. It possesses
good flexibility during both the implanted and sheath-
loaded stage, allowing stenting through curved arteries
over the hip joint. In treated arteries, its self-expanding
force was sufficient to maintain an adequate diameter and,
in addition, the radiopaque markers present at both ends
facilitate deployment at the exact site. During deployment,
however, marked shortening, similar to that exhibited by
the Wallstent, was observed, and this made it somewhat
difficult to accurately place the stent and imposed a risk of
insufficient coverage of the diseased segment due to fur-
ther expansion and shortening during follow-up. The stent
is available in several lengths and diameters; it is, there-
fore, important to measure the lesion accurately, thus en-
suring that the stent chosen is optimal. 
In 88% of patients, symptoms of ischemia improved by
at least one Fontaine stage, and in 64%, improvement of at
least two grades was noted. A favorable result was ob-
tained in stage-II patients: in twelve of the 16 who were
stage IIb and all three who were IIa, clinical symptoms im-
proved to stage I (no symptoms). In stage IV patients
(n=4), the results were poor, however; the symptoms of
three of the four did not improve even after successful
stent placement, and they suffered uncontrolled diabetes
and gangrenous change in their feet. Digital subtraction an-
giography showed multifocal stenoses or occlusions in all
three trifurcating branches of the popliteal artery, and this
was probably the cause of their symptoms. Eventually, the
affected feet or toes were amputated. We believe that if
stents had not already been deployed, more extensive
surgery would probably have been possible. Uncontrolled
diabetes appears, therefore, to be a contraindication for
stent insertion. 
At present, stent patency is limited mainly by early
thrombosis and delayed restenosis. Early stent thrombosis
may be related to technical problems and stent thrombo-
genicity, and delayed restenosis or occlusion can occur due
to intimal hyperplasia (19, 20). In our study, early stent
thrombosis (within one month) was not observed. In two
patients, however, restenosis due to intimal hyperplasia
developed three and 21 months, respectively, after stent
placement. In the patient in whom restenosis (50% of
nominal diameter) was detected by follow-up sonography
21 months after stent placement, no ischemic symptoms
were observed and further evaluation was declined.
During a follow-up period of 27 months, the degree of
restenosis in one of these two patients was unchanged and
he was free of symptoms. In the other, Doppler ultrasound
and digital subtraction angiography performed three
months after stent placement revealed severe (75%) in-
trastent stenosis of the distal portion, though this was suc-
cessfully treated by PTA. In those two patients, angiogra-
phy showed that the superficial femoral arteries were oc-
cluded. Poor runoff has been noted to adversely affect
long-term patency rates in aortofemoral bypass grafts, in il-
Yoon et al.
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With regard to animal experiments in which neointimal
hyperplasia lasted for up to six months, there was no sig-
nificant difference between different stents, including the
Palmaz, Wallstent and nitinol (Memotherm) types (19).
Three to four weeks after insertion of the nitinol stent, the
neointima was well organized, with an endothelial lining,
subintimal fibrosis, and mild infiltration by inflammatory
cells. In an experimental study in which a Niti-S stent was
placed in canine iliac arteries, the neointima was thickest
eight weeks after stent placement and was progressively
replaced by collagen. Compared with previous reports, the
neointimal thickness of the Niti-S stent was acceptable
(17).
In the five patients with complete iliac arterial occlusion,
the hemodynamic and clinical outcomes were not signifi-
cantly different from those of arterial stenoses in the other
20. In those with complete occlusion, the mean systolic
pressure gradient across the lesion improved from 54 to 4
mmHg. The clinical stage of these patients [IIb (n=4) and
III (n=1)] improved to I. During the follow-up period, pa-
tency of the stented segment was well maintained. The
mean ABI in the five patients was 0.84 before the proce-
dure, 1.04 three days after its completion, and 1.02 at the
end of the follow-up period, suggesting good clinical and
hemodynamic outcomes.
The overall complication rate for stent placement has
been reported as 6.7 23.7% (23, 24). In our study, with
the exception of one pseudoaneurysm which was easily
treated by compression, procedure-related complications
were not observed. Though not a major drawback in pri-
mary stent placement, the distal embolization rate has
been reported as 0 17% (25, 26). 
In our study, close contact between the stent-loaded
sheath and the lesion during the procedure seems to have
prevented embolization. In most interventions, distal em-
bolization is prevented though the routine use of an-
tiplatelet agents. The most common of these is aspirin,
though several others, such as dipyridamole and ticlopi-
dine, have also been used. Controlled clinical studies have,
however, failed to demonstrate the antithrombotic efficacy
of dipyridamole where this is used alone (27); ticlopidine,
on the other hand, has proven superior to aspirin for the
prevention of thromboembolism (28). 
In conclusion, the technical success and complication
rates for percutaneous iliac artery revascularization using
the Niti-S stent were favorable, the symptoms of most pa-
tients improved, and patency rates were comparable to
those obtained using other commercially available stents.
We believe, though, that it is necessary to determine the
long-term effectiveness of this stent, and for this, a larger
series of patients should be involved.
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